Cargando…
Novel anti-melanoma treatment: focus on immunotherapy
Melanoma is an intractable cancer that is aggressive, lethal, and metastatic. The prognosis of advanced melanoma is very poor because it is insensitive to chemotherapy and radiotherapy. The incidence of melanoma has been ascending stably for years worldwide, accompanied by increasing mortality. New...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Sun Yat-sen University Cancer Center
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4190435/ https://www.ncbi.nlm.nih.gov/pubmed/25189718 http://dx.doi.org/10.5732/cjc.014.10118 |
_version_ | 1782338510375616512 |
---|---|
author | Hao, Meng-Ze Zhou, Wen-Ya Du, Xiao-Ling Chen, Ke-Xin Wang, Guo-Wen Yang, Yun Yang, Ji-Long |
author_facet | Hao, Meng-Ze Zhou, Wen-Ya Du, Xiao-Ling Chen, Ke-Xin Wang, Guo-Wen Yang, Yun Yang, Ji-Long |
author_sort | Hao, Meng-Ze |
collection | PubMed |
description | Melanoma is an intractable cancer that is aggressive, lethal, and metastatic. The prognosis of advanced melanoma is very poor because it is insensitive to chemotherapy and radiotherapy. The incidence of melanoma has been ascending stably for years worldwide, accompanied by increasing mortality. New approaches to managing this deadly disease are much anticipated to enhance the cure rate and to extend clinical benefits to patients with metastatic melanoma. Due to its high degree of immunogenicity, melanoma could be a good target for immunotherapy, which has been developed for decades and has achieved certain progress. This article provides an overview of immunotherapy for melanoma. |
format | Online Article Text |
id | pubmed-4190435 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Sun Yat-sen University Cancer Center |
record_format | MEDLINE/PubMed |
spelling | pubmed-41904352014-10-15 Novel anti-melanoma treatment: focus on immunotherapy Hao, Meng-Ze Zhou, Wen-Ya Du, Xiao-Ling Chen, Ke-Xin Wang, Guo-Wen Yang, Yun Yang, Ji-Long Chin J Cancer Review Melanoma is an intractable cancer that is aggressive, lethal, and metastatic. The prognosis of advanced melanoma is very poor because it is insensitive to chemotherapy and radiotherapy. The incidence of melanoma has been ascending stably for years worldwide, accompanied by increasing mortality. New approaches to managing this deadly disease are much anticipated to enhance the cure rate and to extend clinical benefits to patients with metastatic melanoma. Due to its high degree of immunogenicity, melanoma could be a good target for immunotherapy, which has been developed for decades and has achieved certain progress. This article provides an overview of immunotherapy for melanoma. Sun Yat-sen University Cancer Center 2014-09 /pmc/articles/PMC4190435/ /pubmed/25189718 http://dx.doi.org/10.5732/cjc.014.10118 Text en Chinese Journal of Cancer http://creativecommons.org/licenses/by-nc-sa/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License, which allows readers to alter, transform, or build upon the article and then distribute the resulting work under the same or similar license to this one. The work must be attributed back to the original author and commercial use is not permitted without specific permission. |
spellingShingle | Review Hao, Meng-Ze Zhou, Wen-Ya Du, Xiao-Ling Chen, Ke-Xin Wang, Guo-Wen Yang, Yun Yang, Ji-Long Novel anti-melanoma treatment: focus on immunotherapy |
title | Novel anti-melanoma treatment: focus on immunotherapy |
title_full | Novel anti-melanoma treatment: focus on immunotherapy |
title_fullStr | Novel anti-melanoma treatment: focus on immunotherapy |
title_full_unstemmed | Novel anti-melanoma treatment: focus on immunotherapy |
title_short | Novel anti-melanoma treatment: focus on immunotherapy |
title_sort | novel anti-melanoma treatment: focus on immunotherapy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4190435/ https://www.ncbi.nlm.nih.gov/pubmed/25189718 http://dx.doi.org/10.5732/cjc.014.10118 |
work_keys_str_mv | AT haomengze novelantimelanomatreatmentfocusonimmunotherapy AT zhouwenya novelantimelanomatreatmentfocusonimmunotherapy AT duxiaoling novelantimelanomatreatmentfocusonimmunotherapy AT chenkexin novelantimelanomatreatmentfocusonimmunotherapy AT wangguowen novelantimelanomatreatmentfocusonimmunotherapy AT yangyun novelantimelanomatreatmentfocusonimmunotherapy AT yangjilong novelantimelanomatreatmentfocusonimmunotherapy |